These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 36864892)
1. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Agarwal R; Pitt B; Palmer BF; Kovesdy CP; Burgess E; Filippatos G; Małyszko J; Ruilope LM; Rossignol P; Rossing P; Pecoits-Filho R; Anker SD; Joseph A; Lawatscheck R; Wilson D; Gebel M; Bakris GL Clin Kidney J; 2023 Feb; 16(2):293-302. PubMed ID: 36864892 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Lerma E; White WB; Bakris G Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754 [TBL] [Abstract][Full Text] [Related]
3. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Agarwal R; Rossignol P; Romero A; Garza D; Mayo MR; Warren S; Ma J; White WB; Williams B Lancet; 2019 Oct; 394(10208):1540-1550. PubMed ID: 31533906 [TBL] [Abstract][Full Text] [Related]
4. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. Pitt B; Agarwal R; Anker SD; Ruilope LM; Rossing P; Ahlers C; Brinker M; Joseph A; Lambelet M; Lawatscheck R; Filippatos GS; JAMA Netw Open; 2022 Oct; 5(10):e2236123. PubMed ID: 36287567 [TBL] [Abstract][Full Text] [Related]
5. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673 [TBL] [Abstract][Full Text] [Related]
6. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. Rossignol P; Williams B; Mayo MR; Warren S; Arthur S; Ackourey G; White WB; Agarwal R Eur J Heart Fail; 2020 Aug; 22(8):1462-1471. PubMed ID: 32452085 [TBL] [Abstract][Full Text] [Related]
7. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. Agarwal R; Joseph A; Anker SD; Filippatos G; Rossing P; Ruilope LM; Pitt B; Kolkhof P; Scott C; Lawatscheck R; Wilson DJ; Bakris GL; J Am Soc Nephrol; 2022 Jan; 33(1):225-237. PubMed ID: 34732509 [TBL] [Abstract][Full Text] [Related]
8. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173 [TBL] [Abstract][Full Text] [Related]
9. Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial. Agarwal R; Rossignol P; Budden J; Mayo MR; Arthur S; Williams B; White WB Kidney360; 2021 Mar; 2(3):425-434. PubMed ID: 35369022 [TBL] [Abstract][Full Text] [Related]
10. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Filippatos G; Anker SD; August P; Coats AJS; Januzzi JL; Mankovsky B; Rossing P; Ruilope LM; Pitt B; Sarafidis P; Teerlink JR; Kapelios CJ; Gebel M; Brinker M; Joseph A; Lage A; Bakris G; Agarwal R Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):183-191. PubMed ID: 36639130 [TBL] [Abstract][Full Text] [Related]
11. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature. Georgianos PI; Agarwal R Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811 [TBL] [Abstract][Full Text] [Related]
12. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Ruilope LM; Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Sarafidis P; Schmieder RE; Joseph A; Rethemeier N; Nowack C; Bakris GL; Hypertension; 2022 Dec; 79(12):2685-2695. PubMed ID: 36252131 [TBL] [Abstract][Full Text] [Related]
13. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B; Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784 [TBL] [Abstract][Full Text] [Related]
14. Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Goulooze SC; Snelder N; Seelmann A; Horvat-Broecker A; Brinker M; Joseph A; Garmann D; Lippert J; Eissing T Clin Pharmacokinet; 2022 Mar; 61(3):451-462. PubMed ID: 34786651 [TBL] [Abstract][Full Text] [Related]